Cargando…

Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis

AIMS/INTRODUCTION: Glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras) are widely used to treat type 2 diabetes. They not only reduce glucose, but also have a positive effect on weight loss. However, few studies have reported the effect of GLP‐1Ras on fat distribution. MATERIALS AND METHODS: PubMed...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Kaixin, Yan, Xiaolu, Gao, Zhe, Hou, Yilin, Lv, Xiuqin, Song, Guangyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248433/
https://www.ncbi.nlm.nih.gov/pubmed/35191185
http://dx.doi.org/10.1111/jdi.13775
_version_ 1784739361229635584
author Duan, Kaixin
Yan, Xiaolu
Gao, Zhe
Hou, Yilin
Lv, Xiuqin
Song, Guangyao
author_facet Duan, Kaixin
Yan, Xiaolu
Gao, Zhe
Hou, Yilin
Lv, Xiuqin
Song, Guangyao
author_sort Duan, Kaixin
collection PubMed
description AIMS/INTRODUCTION: Glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras) are widely used to treat type 2 diabetes. They not only reduce glucose, but also have a positive effect on weight loss. However, few studies have reported the effect of GLP‐1Ras on fat distribution. MATERIALS AND METHODS: PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP‐1Ras and type 2 diabetes, published from inception to June 2021. Our main outcomes were the reductions of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Other anthropometric outcomes were also assessed. We used the Cochrane Collaboration tools to assess the risk of bias in the included studies. The quality of the evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation profiler version 3.6. Review Manager 5.4.1 and Stata 16.0 were used for data analysis. RESULTS: A total of 10 studies involving 541 patients were included. Compared with the control groups, the GLP‐1Ras groups showed reductions in VAT (standard mean difference −0.54, 95% confidence interval [CI] −0.92, −0.17, I (2) = 79%, P = 0.005) and SAT (standard mean difference −0.44, 95% CI −0.60, −0.27, I (2) = 44%, P < 0.00001). In addition, bodyweight (weighted mean difference −3.59, 95% CI −4.30, −2.88, I (2) = 0%, P < 0.00001), waist circumference (weighted mean difference −3.09, 95% CI −4.66, −1.52, I (2) = 70%, P = 0.0001) and body mass index (weighted mean difference −1.11, 95% CI −1.35, −0.86, I (2) = 47%, P < 0.00001) were significantly decreased. According to the Grades of Recommendation, Assessment, Development and Evaluation approach, the level of evidence was low or moderate. CONCLUSION: This study highlights that GLP‐1Ras, especially liraglutide and exenatide, might play an active role in fat distribution in patients with type 2 diabetes. After treatment with GLP‐1Ras, both VAT and SAT decreased, and the decrease of VAT was numerically greater than that of SAT.
format Online
Article
Text
id pubmed-9248433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92484332022-07-05 Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis Duan, Kaixin Yan, Xiaolu Gao, Zhe Hou, Yilin Lv, Xiuqin Song, Guangyao J Diabetes Investig Articles AIMS/INTRODUCTION: Glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras) are widely used to treat type 2 diabetes. They not only reduce glucose, but also have a positive effect on weight loss. However, few studies have reported the effect of GLP‐1Ras on fat distribution. MATERIALS AND METHODS: PubMed, Cochrane, Embase and ClinicalTrials.gov were searched for randomized controlled trials on GLP‐1Ras and type 2 diabetes, published from inception to June 2021. Our main outcomes were the reductions of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Other anthropometric outcomes were also assessed. We used the Cochrane Collaboration tools to assess the risk of bias in the included studies. The quality of the evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation profiler version 3.6. Review Manager 5.4.1 and Stata 16.0 were used for data analysis. RESULTS: A total of 10 studies involving 541 patients were included. Compared with the control groups, the GLP‐1Ras groups showed reductions in VAT (standard mean difference −0.54, 95% confidence interval [CI] −0.92, −0.17, I (2) = 79%, P = 0.005) and SAT (standard mean difference −0.44, 95% CI −0.60, −0.27, I (2) = 44%, P < 0.00001). In addition, bodyweight (weighted mean difference −3.59, 95% CI −4.30, −2.88, I (2) = 0%, P < 0.00001), waist circumference (weighted mean difference −3.09, 95% CI −4.66, −1.52, I (2) = 70%, P = 0.0001) and body mass index (weighted mean difference −1.11, 95% CI −1.35, −0.86, I (2) = 47%, P < 0.00001) were significantly decreased. According to the Grades of Recommendation, Assessment, Development and Evaluation approach, the level of evidence was low or moderate. CONCLUSION: This study highlights that GLP‐1Ras, especially liraglutide and exenatide, might play an active role in fat distribution in patients with type 2 diabetes. After treatment with GLP‐1Ras, both VAT and SAT decreased, and the decrease of VAT was numerically greater than that of SAT. John Wiley and Sons Inc. 2022-03-07 2022-07 /pmc/articles/PMC9248433/ /pubmed/35191185 http://dx.doi.org/10.1111/jdi.13775 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Duan, Kaixin
Yan, Xiaolu
Gao, Zhe
Hou, Yilin
Lv, Xiuqin
Song, Guangyao
Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title_full Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title_fullStr Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title_full_unstemmed Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title_short Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
title_sort effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: a systematic review and meta‐analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248433/
https://www.ncbi.nlm.nih.gov/pubmed/35191185
http://dx.doi.org/10.1111/jdi.13775
work_keys_str_mv AT duankaixin effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis
AT yanxiaolu effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis
AT gaozhe effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis
AT houyilin effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis
AT lvxiuqin effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis
AT songguangyao effectofglucagonlikepeptide1receptoragonistsonfatdistributioninpatientswithtype2diabetesasystematicreviewandmetaanalysis